X

Articles

04Jan

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

0 Comments | | Return |

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 convalescent plasma.  The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment.  Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.

We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines. 

 

 

 

Related

Reminder- Check flights and cargo hours for the 4th of July Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

New Learning Center with New Content Launches on March 30!

A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...

Read More >

CTS St. Louis Implements New Laboratory Information System

On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...

Read More >

Reminder-Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

CTS exhibiting at AABB in San Antonio this weekend!

As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...

Read More >

Subscribe here to receive CTS updates!

Name